Trials / Withdrawn
WithdrawnNCT04516603
Influence of Fampridine on Working Memory in Healthy Subjects
Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Healthy Subjects
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Prof. Dominique de Quervain, MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Accepted
Summary
Proof-of-concept study on the effects of 10 mg fampridine (oral administration) on working memory in healthy participants. The hypotheses is that fampridine improves working memory performance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fampridine SR | Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS). |
| DRUG | Placebo | no active component |
Timeline
- Start date
- 2040-01-01
- Primary completion
- 2041-12-31
- Completion
- 2041-12-31
- First posted
- 2020-08-18
- Last updated
- 2024-12-05
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT04516603. Inclusion in this directory is not an endorsement.